Skip to main content

Table 1 Duration of FQ use and the incidence of AAD

From: Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection

Duration of FQ use

No. of participants

OR (95% CI)

outcome

Reference

Study design

≤ 60

1477 case patients and 147,700 matched control cases

RR = 2.43, 95% CI 1.83–3.22

AA or AD

1

A nested case–control analysis

3–14

1213 hospitalized AA/AD patients

OR = 2.41; 95% CI 1.13–3.71

 

4

A case-crossover design

≤ 60

360,088

HR = 1.66; 95% CI 1.12–2.46

AA or AD

9

Nationwide historical cohort study

 

1,744,360

Adjusted HR = 2.24, 95% CI 2.02–2.49

AA

40

Population-based longitudinal cohort study

  

RR = 2.14; 95% CI 1.93–2.36

AA or AD

33

A systematic review and meta-analysis

 

19,207,552

OR = 2.20; 95% CI 1.92–2.52

AA or AD

12

Cohort and case–control studies

> 14

 

OR = 2.83, 95% CI 1.06–7.57

AAD

42

A prospective population-based study

14–60

1213 hospitalized AA/AD patients

OR = 2.83; 95% CI 1.13–3.71

AA or AD

4

A case-crossover design

61–120

360,088

HR = 0.67; 95% CI 0.40–1.11

None

9

Nationwide historical cohort study

90

27,827,254

HR = 1.31; 95% CI 1.25–1.37

AAA

41

Cohort study

 

27,827,254

HR = 1.60; 95% CI 1.33–1.91

Iliac artery aneurysm

41

Cohort study

 

27,827,254

HR = 1.58; 95% CI 1.39–1.79

Other AAA

41

Cohort study

  1. FQ fluoroquinolones, OR odds ratio, HR hazard ratio, RR adjusted ration, CI confidence interval, AA aortic aneurysm, AD aortic dissection, AAA abdominal aortic aneurysm, AAD aortic aneurysm and dissection